Rallybio holders approve Avenzo merger and $13.90/share cash distribution; close expected Nov. 6

Rallybio Corp

All eight annual-meeting proposals passed; Proposal 1, issuing Rallybio stock to Avenzo holders (>20% and a change of control), won 4,506,703 for vs 15,979 against.
Special cash distribution set at $83.6 million, or $13.90 per share, to holders of record Nov. 5, 2026; transfer agent payment expected Nov. 13, 2026.
Stock trades with due bills Nov. 5-6, 2026 ahead of the Nov. 9 ex-dividend date; investors must hold through the Nov. 6 close to receive the distribution.
Merger expected to close Nov. 6, 2026; Rallybio will be renamed Avenzo Therapeutics, raise authorized shares to 500M from 200M, with a 1-for-2 to 1-for-9 reverse split not done pre-close.
Avenzo 2026 Equity Incentive Plan reserve equals 18% of post-merger shares outstanding; 2026 ESPP reserve 1%, each with annual evergreen increases through 2036.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.